Primary Site >> Colorectal Cancer
Gene >> TPBG
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. PMID: 8180020 |
Ref: Metastasis-associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane. PMID: 7593330 Ref: 5T4 oncofetal antigen expression in ovarian carcinoma. PMID: 11578488 |
Ref: Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. PMID: 9815581 |
Ref: The pattern of expression of the 5T4 oncofoetal antigen on normal, dysplastic and malignant oral mucosa. PMID: 11120484 |
Ref: Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. PMID: 16166432 |
Ref: Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. PMID: 16630022 Ref: Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. PMID: 16740766 Ref: CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PMID: 17205133 |
Ref: Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. PMID: 17671134 |
Ref: Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. PMID: 18060404 Ref: Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. PMID: 18567615 Ref: An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. PMID: 18833005 Ref: Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. PMID: 18990081 |
Ref: Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). PMID: 19221742 |
Ref: Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. PMID: 20948436 Ref: TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development. PMID: 20975327 |
Ref: Suppression of tumour-specific CD4(+) T cells by regulatory T cells is associated with progression of human colorectal cancer. PMID: 22207629 |
Ref: Escalating regulation of 5T4-specific IFN-gamma(+) CD4(+) T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. PMID: 24409450 |
Ref: Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen. PMID: 24736661 Ref: TroVax in colorectal cancer. PMID: 25483641 |
Ref: Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. PMID: 25669203 |
Ref: Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial. PMID: 28880972 |
Ref: A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models. PMID: 29736307 |